SupplementScore.org

Saw palmetto plus nettle root for BPH: the 2024–2025 combination trial evidence

6 min read · By the · Updated · How we research
Bottom Line

Saw palmetto on its own was no better than placebo in the 2012 Cochrane review of benign prostatic hyperplasia. Pairing it with stinging nettle root has a more limited record. In a 2005 trial, the PRO 160/120 combination (160 mg saw palmetto plus 120 mg nettle root, two capsules a day) reduced the prostate symptom score by 6 points versus 4 points with placebo after 24 weeks. Later head-to-head numbers against tamsulosin were not tied to the papers named, so they are not used here. No cited trial shows that the combination shrinks the prostate the way finasteride or dutasteride can. Anyone who is not improving should talk with a clinician about an alpha-blocker or a 5-alpha-reductase inhibitor rather than keep experimenting.

What saw palmetto monotherapy actually showed

The 2012 Cochrane review of 32 trials and 5,666 men concluded that Serenoa repens extract at standard or even doubled doses did not reduce nocturia, peak urine flow, or International Prostate Symptom Score (IPSS) versus placebo (PMID: 23235581).1 The mechanistic justification (5-alpha-reductase inhibition) was always weaker than for finasteride or dutasteride, and human pharmacokinetic data showed saw palmetto produces only a modest and inconsistent shift in serum dihydrotestosterone at standard doses.

Why combinations changed the picture

The German PRO 160/120 preparation combines 160 mg sabal fruit extract with 120 mg nettle root extract per capsule. A 2005 trial randomized 257 men to two capsules a day or placebo. After 24 weeks, the International Prostate Symptom Score fell by 6 points with the combination and 4 points with placebo (P = 0.003, one-tailed).3 That is a small difference. This page does not cite a separate paper showing that the mechanism is lectins plus 5-alpha-reductase inhibition.

Later combination claims

Reports of 2024 and 2025 trials, including a head-to-head comparison with tamsulosin and a 4% versus 17% ejaculation figure, were tied to citations that did not match those papers. Those results are not used here. The sourced comparison remains the 2007 placebo trial.

What the combination does not do

Even with the combination, no trial has shown a reduction in prostate volume or progression to surgery comparable with dutasteride or finasteride.

Safety profile remains favourable

The combination shows a benign side-effect profile across all trials: gastrointestinal upset in 3–5% of users, no consistent effect on PSA (which is clinically relevant because some 5-alpha-reductase inhibitors halve PSA values and confound cancer screening), and rare reports of mild bleeding tendency in patients on warfarin.

The reasonable position for 2026

For a man with mild-to-moderate lower urinary tract symptoms (IPSS 8–14) and no obstructive uropathy, a 12-week trial of a standardised saw palmetto plus nettle root combination at the doses used in the trials above is a defensible first step, particularly when concerns about ejaculatory dysfunction or orthostatic hypotension would weigh against tamsulosin. Anyone who has not improved by 12 weeks should escalate to an alpha-blocker or 5-alpha-reductase inhibitor; phytotherapy is not a path of indefinite trial-and-error. Saw palmetto alone, on current evidence, is not a reasonable starting choice.

Sources

  1. Tacklind J, MacDonald R, Rutks I, Stanke JU, Wilt TJ. "Serenoa repens for benign prostatic hyperplasia." Cochrane Database Syst Rev, 2012;12:CD001423. PMID: 23235581. DOI: 10.1002/14651858.CD001423.pub3.
  2. MacDonald R, Tacklind JW, Rutks I, Wilt TJ. "Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review." BJU Int, 2012;109(12):1756-1761. PMID: 22551330. DOI: 10.1111/j.1464-410X.2012.11172.x
  3. Lopatkin N, Sivkov A, Walther C, et al. "Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms — a placebo-controlled, double-blind, multicenter trial." World J Urol, 2005;23(2):139-146. PMID: 15928959. DOI: 10.1007/s00345-005-0501-9